The anticoagulants apixaban, dabigatran and rivaroxaban are more cost-effective than warfarin in the prevention of strokes among patients with nonvalvular atrial fibrillation, according to a study in Stroke: Journal of the American Heart Association. The costs analyzed in the review were associated with clinical events, visits with doctors, medicines, testing and adverse events.

Related Summaries